Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19682813 | 0.89 | MAOA (0.47) | PBRM1BRD4L3MBTL1HSD17B1ALDH1A1 | |
| SCHEMBL6369671 | 0.89 | TDP1 (0.44) | PBRM1HSD17B10CES1TDP1L3MBTL1 | |
| SCHEMBL8318207 | 0.85 | CASP1 (0.52) | PBRM1HSD17B10CASP1CASP7HRH3 | |
| SCHEMBL7194507 | 0.83 | BCHE (0.39) | PBRM1HSD17B10CES1TDP1L3MBTL1 | |
| SCHEMBL4243389 | 0.81 | CA1 (0.55) | PBRM1HSD17B10CASP1CASP7ALDH1A1 | |
| SCHEMBL1003926 | 0.81 | PBRM1 (0.52) | PBRM1HSD17B10CASP1CASP7BRD4 | |
| Hydrochloric Acid SCHEMBL28058141 | 0.80 | PBRM1 (0.55) | PBRM1HSD17B10CASP1CASP7BRD4 | |
| SCHEMBL8870208 | 0.77 | PBRM1 (0.47) | PBRM1HSD17B10CASP1CASP7BRD4 | |
| SCHEMBL1199335 | 0.76 | PARP10 (0.61) | GRM5 | |
| SCHEMBL6205182 | 0.75 | PNMT (0.45) | PBRM1BRD4HRH3HSD17B1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533985-B2 | Sulfonamide derivative and medicinal use thereof | EA PHARMA CO., LTD. (JP) | 2017-01-03 | — | — | US | disclosed |
| EP-2842945-B1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | EA PHARMA CO LTD (JP) | 2016-10-26 | — | — | EP | disclosed |
| CN-104395297-B | Sulfonamide derivatives and pharmaceutical use thereof | AJINOMOTO CO.,INC. (JP) | 2016-05-04 | — | — | CN | disclosed |
| EP-2842945-A1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | AJINOMOTO CO., INC. (JP) | 2015-03-04 | — | — | EP | disclosed |
| CN-104395297-A | Sulfonamide derivatives and pharmaceutical use thereof | AJINOMOTO KK | 2015-03-04 | — | — | CN | disclosed |
| US-20150051395-A1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | AJINOMOTO CO., LTD. (JP) | 2015-02-19 | — | — | US | disclosed |
| EP-1098891-B1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA GMBH (DE) | 2005-08-10 | — | — | EP | disclosed |
| EP-1098891-A1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2001-05-16 | — | — | EP | disclosed |
| US-6159996-A | Polycyclic thiazolidin-2-ylidene amines, process for their preparation, and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-12-12 | — | — | US | disclosed |
| WO-2000004006-A1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051395-A1 | SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | ITGB4, ITGA4, ITGA2 | PBRM1 1656/4885HSD17B10 4530/4885CASP1 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.